Abstract 3417
Background
Immune-checkpoint inhibitors (ICI) have recently been used in many types of cancers including non-small cell lung cancer (NSCLC). Interstitial lung disease associated with ICI (ICI-ILD) is a serious immune-related adverse event. However, comprehensive clinical characterization of ICI-ILD is still lacking.
Methods
We retrospectively analyzed clinical and imaging data of all consecutive ICI treated patients in Kurashiki Central Hospital (Okayama, Japan) between January 2016 and March 2019. We elucidated clinical characteristics, radiopathological patterns, therapeutic strategies and outcomes of ICI-ILD and analyzed the prognostic factor of ICI-ILD.
Results
Among 316 (222 NSCLC and 94 non-NSCLC) treated with ICI, 35 (11.1%) were diagnosed as ICI-ILD. Of those, NSCLC/gastric cancer/urinary cancer/head and neck cancer/malignant lymphoma were 26/2/2/4/1, respectively: mean age was 69.3 ± 9.0 years; 29 (82.9%) were men; 19 (54.3%) received Nivolumab monotherapy and 10 (28.6%) received Pembrolizumab monotherapy; Best objective response rate until ICI-ILD diagnosis was 48.6% (11/35); The median time (range) from ICI introduction to ICI-ILD was 57 (22-155) days. CTCAE grade 1/2/3 + 4/5 was 10 (28.6%)/14 (40.0%)/7 (20.0%)/4 (11.4%), respectively; Organizing pneumonia was found in 57.1% (20/35) in CT and 66.7% (4/6) in transbronchial lung biopsy; Lymphocyte differential count of bronchoalveolar lavage fluid (range) was 41 (33-60) %; 26 (74.3%) were treated with corticosteroid; 29 (82.9%) had ICI-ILD improved but 6 (17.1%) did not. The median survival time was significantly different between ILD improved group and non-improved group (17.1 months vs 0.8 months, p < 0.001). Multivariate Cox regression analysis demonstrated that only ICI-ILD improvement is a significant prognostic factor (HR: 0.03; 95% CI, 0.003-0.305; p = 0.003).
Conclusions
In our real-world experience, half of ICI-ILD patients had a response toward malignancy. Organizing pneumonia was the most common radiopathological pattern and lymphocyte differential count of bronchoalveolar lavage fluid was elevated in ICI-ILD. If ICI-ILD does not improve, its prognosis may be very poor.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract